Oneness Biotech is fully dedicated to the research and development of new drugs, and adheres to the business philosophy of being science-driven, honest, as well as transparent. Through professional talents, innovative technologies, and the steadfast conviction, we are committed to developing innovative drugs to solve the unmet medical needs.
In March 2021, “Fespixon”, new drug for diabetic foot ulcers (DFU) passed the New Drug Application (NDA) of the Ministry of Health and Welfare and obtained the drug license. In April, Oneness Nanchou Plant completed the PIC/S GMP and GDP certifications for the API plant and the finished pharmaceutical product plant. The R&D, production and marketing of new drugs are perfectly integrated, bringing new hope for diabetic foot ulcers treatment. In order to encourage medical researchers to conduct more in-depth academic researches or clinical applications of “Fespixon” in the treatment of diabetic foot ulcers or other chronic wounds, Oneness Biotech announced a “Regulations Governing the Subsidy for Research Projects” to provide NT$2 million subsidy for innovative research projects. Through filming health education videos such as “What is DFU?”, “Caring for feet” and “Diabetic foot ulcer management and care”, we can increase the public awareness of DFU which allow early diagnosis and treatment of diabetic foot ulcers. For low-income patients with diabetic foot ulcers, Oneness Biotech provides “Fespixon” for free to allow patients to receive treatment as soon as possible. In order to allow patients in other countries to use “Fespixon”, we have sped up our global market access procedures in applying drug license of Southeast Asian countries with the Certificate of Pharmaceutical Product (CPP) and submitted the drug license application in China. Oneness Biotech has also begun the second Phase III clinical trial in the United States, with the goal of entering global market by 2025.
In the past year, the COVID-19 novel coronavirus has had a serious impact on the health of people, society and economy of all countries. As a biotech and new pharmaceuticals company, Oneness Biotech has actively invested in R&D of COVID-19 drugs and developed a new small nucleic acid antiviral drug SNS812 in order to suppress the virus and reduce the amount of virus to achieve the purpose of treatment. In the face of the COVID-19 epidemic, Oneness Biotech quickly established an epidemic command center, set up an epidemic prevention response team to formulate contingency plans, and adopted multi-faceted epidemic prevention measures to provide employees with a safe workplace, continue to care for their mental health, and reduce their stress caused by the epidemic.
In the past year, the global COVID-19 outbreak has affected all sectors of the world economy, public health and society. Being a biotech and pharmaceutical company, Oneness Biotech has actively invested in R&D of COVID-19 drugs and developed a new small-interfering RNA antiviral drug SNS812 in order to suppress the virus and reduce the amount of virus to achieve the purpose of treatment. In the face of the COVID-19 epidemic, Oneness Biotech quickly established an epidemic command center, set up an epidemic prevention response team to formulate contingency plans, and adopted multi-faceted epidemic prevention measures to provide employees with a safe workplace, continue to care for their mental health, and reduce their stress caused by the epidemic.
In 2020, Oneness Biotech established the “Corporate Social Responsibility Committee”, which comprises high-level management to practice ESG with all employees. With the joint efforts of our colleagues, we completed the first voluntary ESG report last year, conducted an external performance evaluation of the Board of Directors, reported the intellectual property management plan and risk management operation status to the Board of Directors, disclosed the communication with stakeholders and other evaluation indicators. In the “ 7th Corporate Governance Evaluation (2020)”, Oneness has risen to the top 6% to 20% among the OTC-listed companies. This year, Oneness Biotech keeps dedicating to the corporate governance spirit of integrity and transparency. In addition to the quarterly institutional investor conferences and the daily responses to investor questions on the official website, we adhere to meet international standards, publish the annual report, interim financial statement, shareholders’ meeting notices and agenda in English on the official website, and release material information in English in a timely manner, all as part of the efforts to achieve the goal of ranking top 5% of Corporate Governance Evaluation.
In recent years, natural disasters such as floods, droughts, and abnormally high temperatures caused by extreme climate change have had a lasting impact on the ecological environment. In the face of climate change, Oneness Biotech will introduce the “Task Force on Climate-related Financial Disclosures (TCFD)” project through the TCFD framework to identify climate-related risks and opportunities, the impacts on operation and financial, and to propose strategy and countermeasure to manage the climate-related risk. We will also conduct a carbon footprint verification project in order to manage and propose carbon reduction plan.
The new drug business is established based on benefiting people to solve human life and health problems with scientific innovation. Oneness Biotech has developed a new drug business that saves people and benefits others from the perspectives of life and health. We are also dedicated to caring and giving back to society from the perspectives of happiness and passion for life. To build a sustainable company, apart from engaging in R&D and innovation, Oneness Biotech will adhere to practice ESG , with the spirit of “what is taken from society is given back to society”, to share the “health, happiness, and love” brought about by innovation with our employees, shareholders, patients, and society.